Morgan Stanley Adjusts Target Price for SBP GROUP, Maintains Positive Outlook

Stock News

06/01

Morgan Stanley has revised its financial forecasts for SBP GROUP (01177), incorporating the newly licensed drug bepirovirsen (HBV ASO) into its projections, with revenue contributions expected to commence from 2027.

The analysis also removes assumptions regarding dividend income from Sinovac LS starting in 2026, following updated management guidance.

Consequently, earnings per share estimates for 2026 through 2028 have been reduced by 8%, 7%, and 7%, respectively.

Additional adjustments were made to working capital and capital expenditure assumptions to better align with recent operational trends.

The firm has lowered its target price from HK$8.3 to HK$7.8 while reiterating its "Overweight" rating on the stock.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1161018441"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161018441\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161018441?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161018441","market":"us","top_or_hot":-1,"title":"Morgan Stanley Adjusts Target Price for SBP GROUP, Maintains Positive Outlook","media":"Stock News","content":"<p>Morgan Stanley has revised its financial forecasts for SBP GROUP (01177), incorporating the newly licensed drug bepirovirsen (HBV ASO) into its projections, with revenue contributions expected to commence from 2027.<br><br>The analysis also removes assumptions regarding dividend income from Sinovac LS starting in 2026, following updated management guidance.<br><br>Consequently, earnings per share estimates for 2026 through 2028 have been reduced by 8%, 7%, and 7%, respectively.<br><br>Additional adjustments were made to working capital and capital expenditure assumptions to better align with recent operational trends.<br><br>The firm has lowered its target price from HK$8.3 to HK$7.8 while reiterating its \"Overweight\" rating on the stock.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Adjusts Target Price for SBP GROUP, Maintains Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Adjusts Target Price for SBP GROUP, Maintains Positive Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley has revised its financial forecasts for SBP GROUP (01177), incorporating the newly licensed drug bepirovirsen (HBV ASO) into its projections, with revenue contributions expected to commence from 2027.<br><br>The analysis also removes assumptions regarding dividend income from Sinovac LS starting in 2026, following updated management guidance.<br><br>Consequently, earnings per share estimates for 2026 through 2028 have been reduced by 8%, 7%, and 7%, respectively.<br><br>Additional adjustments were made to working capital and capital expenditure assumptions to better align with recent operational trends.<br><br>The firm has lowered its target price from HK$8.3 to HK$7.8 while reiterating its \"Overweight\" rating on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YS42.EUR","symbol_name":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","start_time":0,"source_url":"","article_id":"1161018441","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161018441","pubTimestamp":1780301675,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Morgan Stanley has revised its financial forecasts for SBP GROUP (01177), incorporating the newly licensed drug bepirovirsen (HBV ASO) into its projections, with revenue contributions expected to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","EWH":"香港ETF-iShares MSCI","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1589":"北水核心资产","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01477":"欧康维视生物-B","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","01177":"中国生物制药","BK1574":"生物医药B类股"},"translate_title":"摩根士丹利调整SBP集团目标价，维持正面展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1,"01477":1,"EWH":1},"content_text":"Morgan Stanley has revised its financial forecasts for SBP GROUP (01177), incorporating the newly licensed drug bepirovirsen (HBV ASO) into its projections, with revenue contributions expected to commence from 2027.The analysis also removes assumptions regarding dividend income from Sinovac LS starting in 2026, following updated management guidance.Consequently, earnings per share estimates for 2026 through 2028 have been reduced by 8%, 7%, and 7%, respectively.Additional adjustments were made to working capital and capital expenditure assumptions to better align with recent operational trends.The firm has lowered its target price from HK$8.3 to HK$7.8 while reiterating its \"Overweight\" rating on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}